Immunosenescence and cancer

Biogerontology

Volumn 18, Issue 4, 2017, Pages 717-721

  Pawelec, Graham ^a,b,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer immunotherapy; Checkpoint blockade; Immunosenescence; Ipilimumab; Neoantigen

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; TUMOR ANTIGEN; CANCER VACCINE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AGE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSENESCENCE; MALIGNANT NEOPLASM; MELANOMA; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; AGING; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PATHOLOGY; PROCEDURES; RISK FACTOR; TUMOR ESCAPE;

AGE FACTORS; AGING; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CANCER VACCINES; HUMANS; IMMUNOSENESCENCE; IMMUNOTHERAPY; NEOPLASMS; RISK FACTORS; TUMOR ESCAPE;

EID: 85013191507     PISSN: 13895729     EISSN: 15736768     Source Type: Journal    
DOI: 10.1007/s10522-017-9682-z     Document Type: Article

References (32)

1. Bailur JK, Derhovanessian E, Gueckel B, Pawelec G (2015) Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients. J Immunother Cancer 3:45. doi:10.1186/s40425-015-0090-0
2. Baldwin RW (1955) Immunity to methylcholanthrene-induced tumours in inbred rats following atrophy and regression of the implanted tumours. Br J Cancer 9(4):652–657
3. Burnet M (1973) Aging and immunological surveillance. Triangle 12(4):159–162
4. Chiarion Sileni V, Pigozzo J, Ascierto PA, Grimaldi AM, Maio M, Di Guardo L et al (2014) Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res 33:30. doi:10.1186/1756-9966-33-30
5. Chiu YL, Lin CH, Sung BY, Chuang YF, Schneck JP, Kern F et al (2016) Cytotoxic polyfunctionality maturation of cytomegalovirus-pp65-specific CD4+ and CD8+ T-cell responses in older adults positively correlates with response size. Sci Rep 6:19227. doi:10.1038/srep19227
6. Derhovanessian E, Maier AB, Beck R, Jahn G, Hahnel K, Slagboom PE et al (2010) Hallmark features of immunosenescence are absent in familial longevity. J Immunol 185(8):4618–4624. doi:10.4049/jimmunol.1001629
7. Di Benedetto S, Derhovanessian E, Steinhagen-Thiessen E, Goldeck D, Muller L, Pawelec G (2015) Impact of age, sex and CMV-infection on peripheral T cell phenotypes: results from the Berlin BASE-II Study. Biogerontology 16(5):631–643. doi:10.1007/s10522-015-9563-2
8. Effros RB, Pawelec G (1997) Replicative senescence of T cells: does the Hayflick limit lead to immune exhaustion? Immunol Today 18(9):450–454
9. Fulop T, Dupuis G, Baehl S, Le Page A, Bourgade K, Frost E et al (2016) From inflamm-aging to immune-paralysis: a slippery slope during aging for immune-adaptation. Biogerontology 17(1):147–157. doi:10.1007/s10522-015-9615-7
10. Helissey C, Vicier C, Champiat S (2016) The development of immunotherapy in older adults: new treatments, new toxicities? J Geriatr Oncol 7(5):325–333. doi:10.1016/j.jgo.2016.05.007
11. Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR et al (2017) Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18(1):31–41. doi:10.1016/S1470-2045(16)30624-6
12. Hurez V, Daniel BJ, Sun L, Liu AJ, Ludwig SM, Kious MJ et al (2012) Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. Cancer Res 72(8):2089–2099. doi:10.1158/0008-5472
13. Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z et al (2013) Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res 1(4):235–244. doi:10.1158/2326-6066.CIR-13-0068
14. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ et al (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450(7171):903–907. doi:10.1038/nature06309
15. Ledford H (2011) Melanoma drug wins US approval. Nature 471(7340):561. doi:10.1038/471561a
16. Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P et al (2016) baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 22(12):2908–2918. doi:10.1158/1078-0432.CCR-15-2412
17. McDermott D, Lebbe C, Hodi FS, Maio M, Weber JS, Wolchok JD et al (2014) Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 40(9):1056–1064. doi:10.1016/j.ctrv.2014.06.012
18. Pawelec G (2012) Hallmarks of human “immunosenescence”: adaptation or dysregulation? Immun Ageing 9(1):15. doi:10.1186/1742-4933-9-15
19. Pawelec G (2014) Immunosenenescence: role of cytomegalovirus. Exp Gerontol 54:1–5. doi:10.1016/j.exger.2013.11.010
20. Pawelec G, Koch S, Griesemann H, Rehbein A, Hahnel K, Gouttefangeas C (2006) Immunosenescence, suppression and tumour progression. Cancer Immunol Immunother 55(8):981–986. doi:10.1007/s00262-005-0109-3
21. Pawelec G, Lustgarten J, Ruby C, Gravekamp C (2009) Impact of aging on cancer immunity and immunotherapy. Cancer Immunol Immunother 58(12):1907–1908
22. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K (1981) Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59(6):895–900
23. Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN et al (2004) Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 27(6):478–479
24. Schreiber K, Arina A, Engels B, Spiotto MT, Sidney J, Sette A et al (2012) Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res 18(9):2526–2533. doi:10.1158/1078-0432.CCR-12-0127
25. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–1030. doi:10.1200/JCO.2013.53.0105
26. Valmori D, Souleimanian NE, Hesdorffer CS, Old LJ, Ayyoub M (2005) Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals. Clin Immunol 117(2):161–167. doi:10.1016/j.clim.2005.07.004
27. Verschoor CP, Johnstone J, Millar J, Dorrington MG, Habibagahi M, Lelic A et al (2013) Blood CD33(+)HLA-DR(−) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol 93(4):633–637. doi:10.1189/jlb.0912461
28. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E et al (2015) Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 35(Suppl):S185–S198. doi:10.1016/j.semcancer.2015.03.004
29. Ward JP, Gubin MM, Schreiber RD (2016) The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer. Adv Immunol 130:25–74. doi:10.1016/bs.ai.2016.01.001
30. Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM et al (2012) Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 30(15):1835–1841. doi:10.1200/JCO.2011.40.2271
31. Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM et al (2014) Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res 20(6):1601–1609. doi:10.1158/1078-0432.CCR-13-2508
32. Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K et al (2016) Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. doi:10.1158/1078-0432.CCR-16-0127